Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 26 2023 - 7:00AM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the
“Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced the Company
will participate in a fireside chat at Chardan’s 7th Annual Genetic
Medicines Conference on Tuesday, October 3rd at 8:00 a.m. ET.
The live webcast can be accessed via the Investors section of
the Silence website at www.silence-therapeutics.com. An archived
replay of the webcast will be available following the
conference.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include zerlasiran designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230926933986/en/
Enquiries: Silence Therapeutics plc Gem Hopkins,
Head of IR and Corporate Communications ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
From Aug 2023 to Aug 2024